Stock Quote (NASDAQ: NSTG)
Price:
13.93
Change:
+ 0.02
Day High:
14.16
Day Low:
13.91
Volume:
10,900
1:00 PM ET on Dec 24, 2014
Delayed at least 20 minutes.
Provided by eSignal.


Search Investor Relations

Press Releases

All Releases
View Summary PRESS RELEASEDec 22, 2014
NanoString Technologies to Present at J.P. Morgan 33rd Annual Healthcare Conference
read more
View Summary PRESS RELEASEDec 15, 2014
NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium
read more
View Summary PRESS RELEASEDec 08, 2014
NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis
read more
View Summary PRESS RELEASEDec 01, 2014
NanoString Technologies Announces Prosigna Presentations at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium
read more
View Summary PRESS RELEASENov 07, 2014
NanoString Technologies to Present at Canaccord Genuity Medical Technology and Diagnostics Forum
read more
View Summary PRESS RELEASENov 04, 2014
NanoString Technologies Releases Financial Results for Third Quarter of 2014
read more
View Summary PRESS RELEASEOct 21, 2014
NanoString Announces Publication in the Journal of Clinical Oncology Showing the Prosigna Assay Identifies Women With a Low Risk of Late Distant Recurrence of Breast Cancer
read more
View Summary PRESS RELEASEOct 09, 2014
NanoString Technologies to Release Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014
read more
View Summary PRESS RELEASEOct 06, 2014
NanoString Collaborates with Brigham and Women's Hospital in Boston to Accelerate Translation of Genomic Discoveries into Clinical Diagnostics in Oncology
read more
View Summary PRESS RELEASESep 09, 2014
NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research
read more
View Summary PRESS RELEASEAug 27, 2014
NanoString Announces Unexpected Death of Chief Medical Officer, J. Wayne Cowens, MD
read more
View Summary PRESS RELEASEAug 21, 2014
NanoString Technologies to Present at Upcoming Investor Conferences
read more
View Summary PRESS RELEASEAug 05, 2014
NanoString Technologies Receives Market Approval From the Australian Therapeutic Goods Administration for Its Prosigna Breast Cancer Prognostic Gene Signature Assay
read more
View Summary PRESS RELEASEAug 05, 2014
NanoString Technologies Releases Financial Results for Second Quarter of 2014
read more
View Summary PRESS RELEASEJul 29, 2014
NanoString Technologies Introduces New Universal Junction Probe Design for Detecting Gene Fusions
read more
View Summary PRESS RELEASEJul 21, 2014
NanoString Technologies to Release Second Quarter 2014 Financial Results and Host Conference Call on Tuesday, August 5, 2014
read more
View Summary PRESS RELEASEJun 11, 2014
NanoString Technologies to Participate in the JMP Securities Healthcare Conference 2014
read more
View Summary PRESS RELEASEJun 03, 2014
NanoString Technologies Enters into Biomarker Companion Diagnostic Collaboration with Celgene Corporation to Support Development of REVLIMID as Treatment for Patients with Diffuse Large B-Cell Lymphoma
read more
View Summary PRESS RELEASEMay 19, 2014
NanoString Technologies to Participate in the Jefferies 2014 Global Healthcare Conference
read more
View Summary PRESS RELEASEMay 07, 2014
NanoString Technologies Releases First Quarter 2014 Financial Results
read more
Showing 1-20 of 102 Page: 1 2 3 4 5 6  Next 20